Silke Stegemann Quotes (8 Quotes)

This is a good building block for Bayer.

The company's salt acquisitions are paying off big time thanks to the winter weather.

The results were in line. The chemicals cycle is humming right now. The high dividend is not surprising, seeing the growth in profit.

All of the company's business segments have contributed strongly to the earnings improvement, which shows that the past years' efforts to improve efficiency have paid off.

Bayer has now manifest its will to move forward. This is positive because now we know they can stick to their time frame.

It's clearly BASF's strategic thinking not to give in and raise the price unless they get some information that justifies it.

The pain threshold is around 40. They can't go a lot over 40 without the capital markets seeing that negatively. There is a point where a price would not justify the transaction.

This is a good amendment of Bayer's cardiology and hematology portfolio.